Neuropace (NPCE) vs Avita Medical (RCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Avita Medical (RCEL) has outperformed Neuropace (NPCE) over the past year, gaining 138.6% versus a gain of 19.8%. Over five years, NPCE leads with a -18.6% price change compared with -24.9% for RCEL. Neuropace is the larger company by market cap ($425.3 million vs $412.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NPCE | RCEL |
|---|---|---|
| Share price | $12.39 | $13.33 |
| Market cap | $425.28M | $412.25M |
| 1-day change | -2.90% | +2.15% |
| YTD return | -17.36% | +278.26% |
| 1-year return | +19.81% | +138.57% |
| 5-year return | -18.57% | -24.87% |
| EPS (TTM) | $-0.57 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $19.60 | $13.50 |
| 52-week low | $9.22 | $3.22 |
| Distance from 52-week high | -36.79% | -1.26% |
| Analyst consensus | none | none |
| Avg. price target upside | +61.42% | -9.75% |
| Average volume | 169.86K | 441.70K |
| Shares outstanding | 34.32M | 30.93M |
| Employees | 220 | 226 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCEL has outperformed NPCE by 118.8 percentage points over the past year.
About Neuropace
NPCE stock →NeuroPace, Inc. operates as a medical device company in the United States.
Health Care · Medical/Dental Instruments · 220 employees
About Avita Medical
RCEL stock →AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions.
Health Care · Medical/Dental Instruments · 226 employees
NPCE vs RCEL FAQ
Which is bigger, Neuropace or Avita Medical?
Neuropace (NPCE) is larger, with a market capitalization of $425.28M compared with $412.25M for Avita Medical (RCEL).
Which stock has performed better over the past year, NPCE or RCEL?
RCEL returned +138.57% over the past 12 months, compared with +19.81% for NPCE (price return, excluding dividends). Past performance does not predict future results.
Are Neuropace and Avita Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.